公司简介：BluePen生物标志物有限责任公司——综合生物标志物解决方案。

Company profile: BluePen Biomarkers LLC – integrated biomarker solutions.

作者信息

Blair Ian A, Mesaros Clementina, Lilley Patrick, Nunez Matthew

机构信息

BluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; BluePen Biomarkers LLC, 3401 Grays Ferry Avenue, Building 212, Suite 132, Philadelphia, PA 19146-2701, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.

Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Penn SRP Center, University of Pennsylvania, Philadelphia, PA 19104-6160, USA; Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104-6160, USA.

出版信息

Future Sci OA. 2016 Jun 9;2(2):FSO124. doi: 10.4155/fsoa-2016-0031. eCollection 2016 Jun.

DOI:10.4155/fsoa-2016-0031

PMID:28031971

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5137845/

Abstract

BluePen Biomarkers provides a unique comprehensive multi-omics biomarker discovery and validation platform. We can quantify, integrate and analyze genomics, proteomics, metabolomics and lipidomics biomarkers, alongside clinical data, demographics and other phenotypic data. A unique bio-inspired signal processing analytic approach is used that has the proven ability to identify biomarkers in a wide variety of diseases. The resulting biomarkers can be used for diagnosis, prognosis, mechanistic studies and predicting treatment response, in contexts from core research through clinical trials. BluePen Biomarkers provides an additional groundbreaking research goal: identifying surrogate biomarkers from different modalities. This not only provides new biological insights, but enables least invasive, least-cost tests that meet or exceed the predictive quality of current tests.

摘要

BluePen生物标志物提供了一个独特的综合性多组学生物标志物发现与验证平台。我们能够对基因组学、蛋白质组学、代谢组学和脂质组学生物标志物以及临床数据、人口统计学数据和其他表型数据进行量化、整合和分析。我们采用了一种独特的受生物启发的信号处理分析方法，该方法已被证明有能力在多种疾病中识别生物标志物。所得到的生物标志物可用于从核心研究到临床试验等各种背景下的诊断、预后、机制研究以及预测治疗反应。BluePen生物标志物还提供了一个突破性的研究目标：从不同模式中识别替代生物标志物。这不仅能提供新的生物学见解，还能实现侵入性最小、成本最低的检测，且这些检测的预测质量能达到或超过当前检测。